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Abstract
Our genomes contain the blueprint of what makes us human and many indications as to why we develop disease.
Until the last 10 years, most studies had focussed on protein-coding genes, more speciﬁcally DNA sequences coding
for proteins. However, this represents less than 5% of our genomes. The other 95% is referred to as the ‘dark matter’
of our genomes, our understanding of which is extremely limited. Part of this ‘dark matter’ includes regions that give
rise to RNAs that do not code for proteins. A subset of these non-coding RNAs are long non-coding RNAs (lncRNAs),
which in particular are beginning to be dissected and their importance to human health revealed. To improve our
understanding and treatment of disease it is vital that we understand the molecular and cellular function of lncRNAs,
and how their misregulation can contribute to disease. It is not yet clear what proportion of lncRNAs is actually func-
tional; conservation during evolution is being used to understand the biological importance of lncRNA. Here, we pre-
sent key themes within the ﬁeld of lncRNAs, emphasising the importance of their roles in both the nucleus and the
cytoplasm of cells, as well as patterns in their modes of action. We discuss their potential functions in development
and disease using examples where we have the greatest understanding. Finally, we emphasise why lncRNAs can serve
as biomarkers and discuss their emerging potential for therapy.
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Introduction
Only 4% of the human genome codes for proteins, corre-
sponding to ~20 000 protein-coding genes, whereas
~85% of the genome can be transcribed into RNA. These
additional transcriptional events represent part of the
‘dark matter’ of our genome. If these RNAs do not code
for proteins, what do they do? Until relatively recently,
most research focused on understanding the function
and deregulation during disease of the 4% of the genome
that codes for proteins. If we are truly to understand the
genetic causes of disease, we need to look outside
protein-coding sequences, particularly at regions of
non-coding transcription. These regions produce a range
of types and sizes of non-coding RNAs, the most numer-
ous of which are the long non-coding RNAs (lncRNAs).
Our understanding of lncRNAs has been transformed in
the last 10 years. Nonetheless, relatively few lncRNAs
have been characterised in detail and even fewer have
had their functions characterised. Many lncRNAs have
been found to be associated with a range of human
diseases, but our understanding remains limited on
exactly how these lncRNAs contribute to disease.
What are lncRNAs?
LncRNAs are RNAs of >200 nucleotides (nt) in length
that are not thought to code for proteins. Although our
appreciation and understanding of lncRNA function
and importance has exploded in the last decade, the ﬁrst
lncRNAs were discovered in the 1990s: BC200, H19
[1], and Xist [2]. In the post-genomic era, extensive
and deep RNA-Seq has revealed the existence of huge
numbers of novel RNA transcripts, including lncRNAs.
Many of these novel transcripts are low in abundance
and so were not previously identiﬁed. Several consortia
have been responsible for sequencing RNA from a vari-
ety of tissues, cell types, organisms, and disease states,
and we now have a much more precise view of which
RNA transcripts are expressed, and when and where
(GENCODE [3], GTEX [4], FANTOM [5]).
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LncRNA genes are annotated as such because their
RNAs do not contain large open reading frames that
encode protein products (>100 amino acids). Of interest,
although the number of protein-coding genes does not
substantially vary between Drosophila and human, the
number of lncRNA genes does (Figure 1). Therefore,
lncRNAs could represent part of the regulation system
that enables higher eukaryotes to be more complex.
The lncRNA ﬁeld now represents one of the most
exciting and fast-moving ﬁelds in biology. Although
our understanding of lncRNAs has increased, a key
question remains: how many lncRNAs are functional,
or are the majority of lncRNAs the result of spurious
transcription events? Experimental evidence suggests
that >80% of lncRNAs possess biochemical activity
such as protein binding [6]. However, the importance
or function of most of these lncRNA–protein interac-
tions has yet to be validated. Although the function of
many lncRNAs remains elusive, many have been shown
to be associated with human health and disease. A key
avenue going forward will be to dissect how lncRNAs
that contribute to disease do so mechanistically.
Categories of lncRNA
The molecular nature of lncRNAs varies and has the
potential to inﬂuence their function and localisation.
Approximately 50% of lncRNAs possess a polyA tail
and 98% of human lncRNAs are spliced [7], similar to
mRNAs. Many lncRNAs also possess m7G caps. These
mRNA-like features contribute to the ability of many
lncRNAs to exit the nucleus and enter into pathways in
which mRNAs take part. The majority of research over
the last 10 years has focused on those lncRNAs that
remain in the nucleus, but sequencing RNAs in the cyto-
plasm has revealed that many lncRNAs are also present
in the cytoplasm. The relative abundance of an lncRNA
between the nucleus and cytoplasm can help reveal
function and interacting partners. Although many simi-
larities exist between lncRNAs and mRNAs, a key
molecular difference is their cross-species conservation;
lncRNAs are not well conserved.
LncRNAs can be categorised in several different ways,
most simply by their genomic location and structure.
These are not mutually exclusive categories, however.
This method of categorisation can suggest potential
lncRNA function but does not infer mechanism of action.
Intergenic lncRNAs (lincRNAs) are those lncRNAs that
do not overlap with any other genes (protein-coding or
non-coding) and are >1 kb away from neighbouring
genes (Figure 2A). These are the most straightforward
lncRNAs to which to assign function because genomic
mutations can be unequivocally assigned [e.g. clustered
regularly interspaced short palindromic repeats
(CRISPR)]. Many lncRNAs overlap other genes and
can either be in the sense or anti-sense orientation to those
other genes. Anti-sense lncRNAs inherently possess
sequence elements that will base pair to other RNAs, that
is, mRNAs from protein-coding genes they are anti-sense
to (Figure 2B). Sense lncRNAs are located within other
genes, but in the sense direction (Figure 2C). lncRNAs
produced from within the introns of other genes are
termed intronic lncRNAs (Figure 2D). The ﬁnal group
are lncRNA genes, which are transcribed from the same
region in the genome as another gene, but in the opposite
direction: bi-directional lncRNAs (Figure 2E). Inter-
genic and anti-sense are by far the most common types
of lncRNAs in humans (Figure 2F).
The link between lncRNA categories and potential
function arises from the lncRNA’s genomic location rel-
ative to potential target genes. The interaction of
lncRNAs and target genes could take place at the site
of transcription or somewhere else in the cell. Anti-sense
lncRNAs have the potential to regulate their anti-sense
genes at the point of transcription, acting in cis. Equally,
lncRNAs can be transported to other locations in the cell,
termed trans-acting lncRNAs (see the glossary for deﬁ-
nitions). On the simplest level, this might also be at the
Figure 1. Numbers of different types of genes in humans and selected other eukaryotes. Data from Homo sapiens: GENCODE Release (version
30) [3], Mus musculus: GENCODE Release (version M21) [3], Rattus norvegicus: Ensembl RGSC assembly (v6.0) [111], Danio rerio: Ensembl
(GRCz11) [111], Drosophila melanogaster: FlyBase (FB2019_02 R6.27) [112].
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point of transcription of the target gene, which is else-
where in the genome. The ability of lncRNAs to act in
trans comes from their ability to base-pair speciﬁcally
with other RNAs and DNA, as well as to bind to proteins
(Figure 3). These lncRNA complexes can then play roles
in a number of gene expression processes and fall into
several key mechanistic categories. lncRNAs can act as
scaffolds, providing a site for other interactions. More
generally, they can act to recruit protein complexes,
which can be based on their sequence speciﬁcity. Form-
ing lncRNA–protein complexes is an essential aspect for
many lncRNA functions characterised so far. Some of
these interactions can act as decoys, preventing proteins
accessing other RNAs (RBP decoy). Alternatively,
lncRNAs can act through speciﬁc base-pairing with
other RNAs, such as microRNAs (miRNAs). This can
act to sponge miRNAs from other binding events.
lncRNA–mRNA interactions can also act to regulate
mRNA levels by increasing or decreasing their stability.
One of the most controversial areas of lncRNA biol-
ogy is whether they are functional at all. Although func-
tions have been characterised for some lncRNAs, they
remain the minority. Much evidence suggests that the
majority of lncRNAs are not functional [8]. Some
lncRNAs are thought only to possess activity as a result
of their transcription; the lncRNA molecules produced
from these transcription events do not have functions.
Conservation and evolution of lncRNAs
Traditionally, evolutionary conservation has been used
as a proxy for functionality. However, when we compare
lncRNAs to canonical protein-coding genes, they are
found to be poorly conserved at the sequence level.
lncRNAs also often lack orthologues in other species,
and upon comparison with protein-coding sequences or
mRNA untranslated regions (UTRs), lncRNA exons
are found to evolve at a faster rate [9,10]. This provides
evidence that lncRNA genes are ‘junk DNA’, and has
led to the hypothesis that lncRNA transcripts are the
products of pervasive transcription, a common phenom-
enon often dismissed as ‘biological noise’.
Despite this, lncRNAs are in fact under stronger selec-
tive pressure than neutrally evolving sequences such as
introns [9,11], and their apparent lack of sequence con-
servation cannot be taken at face value. Many of the
mechanisms of action of lncRNAs have low sequence
constraints. For example, interacting with and sequester-
ing RNA-binding proteins (RBPs) requires sequence
conservation over only small portions of the total
sequence, in the range of 10 nt.
Generally, lncRNA genes are also small relative to
protein-coding genes, and this shortening of potential
areas of conserved sequence reduces the effectiveness
of standard bioinformatic detection methods. Solving
Figure 2. Categories of lncRNA. Types of lncRNAs based on their genomic position, orientation, and relative location to nearby protein-coding
genes. (A) intergenic, (B) anti-sense, (C) sense, (D) intronic, and (E) bi-directional. lncRNA genes are marked in purple and protein-coding
sequences in yellow. (F) Proportion of lncRNAs present in the human genome by location. Annotation from Gencode January 2019 (release
29, GRch38) [3]. Created using BioRender.
Figure 3. The principle mechanisms governing lncRNA interactions.
lncRNAs have been found to interact with (A) DNA, via Hoogstein
bonding to form triple helical structures, (B) RNA, via Watson–
Crick–Franklin (hydrogen) base-pairing, or (C) proteins. These inter-
actions underlie all effector functions elicited by lncRNAs studied to
date. Created using BioRender.
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this issue is an ever-growing area of research and
includes the adaptation of existing methods and the
development of new ones, for example, methods that
focus on the promoter regions of lncRNAs [12]. Within
vertebrates, thousands of homologues for human lincR-
NAs have now been found with shared expression pat-
terns, despite sharing very short patches of sequence
conservation [13]. This opens the possibility that far
more lncRNAs are in fact functional.
LncRNAs are also found to be syntenically conserved
across multiple species. The human lncRNA CHASERR
(CHD2 adjacent, suppressive regulatory RNA) is found
upstream ofChd2 (chromodomain helicaseDNAbinding
protein 2) in both mice and humans and exhibits
further conservation throughout the vertebrate lineage
(Table 1). This has provided an ideal model to investigate
CHASERR as a potential target to control levels of Chd2,
a protein linked to human neuronal diseases ranging from
epilepsy to neurodevelopmental delay [14,15].
Another lncRNA, LINC00261, exhibits a lower level
of sequence conservation than CHASERR. It shares only
some sequence homology between mammals and ﬁsh in
the ﬁrst exon (Table 1). However, LINC00261 is also
syntenically homologous in a wide range of species,
from humans to sea urchins [13]. Found downstream of
FOXA2, LINC00261 is downregulated in multiple can-
cers and its overexpression inhibits cancer cell invasion,
proliferation, and migration [16]. In many cases, despite
a lack of detectable sequence homology, the act of tran-
scription of these syntenic lncRNAs could affect the
expression of the neighbouring gene, demonstrating a
conserved position and cis-regulatory function.
For the majority of conserved lncRNAs, only a moder-
ate level of sequence identity is observed [17]. This is
demonstrated by Cerox1, an intergenic, bi-directional
lncRNA found in mice (Table 1). Cerox1 regulates the
abundance of the mitochondrial complex 1 transcript by
acting as a miRNA decoy, therefore modulating its activ-
ity. Although Cerox1 is conserved at the sequence level
and is syntenically homologous with a human homo-
logue, the level of conservation drops rapidly inmore dis-
tant species. Across eutherian mammals, conservation is
found only in the second exon of Cerox1 [18].
Of interest, the regulation and tissue speciﬁcity of
lncRNAs are conserved to a level comparable to mRNAs
[13]. Speciﬁcally, conservation of lncRNA promoters is
as strong as that of protein-coding gene promoters [19].
This suggests that selective constraints are often acting
at the transcriptional level. However, lincRNA transcrip-
tion also evolves at a rapid rate; only 72% of human
lincRNAs are also expressed in macaque, compared to
98% of human protein-coding genes in all primates [19].
A further complication in the identiﬁcation of con-
served lncRNAs is their evolution; the origin of
lncRNAs is for the most part unknown. They also evolve
rapidly, with the majority of lncRNAs found to be line-
age speciﬁc [13]. Due to the low levels of sequence con-
servation, it is generally assumed that lncRNAs are
unlikely to evolve via gene duplication, a common
mechanism for protein-coding genes. Potential routes
include protein-coding genes losing their original func-
tion via truncation and loss of coding capacity and
becoming lncRNAs. This mechanism is thought to
account for a proportion of conserved lncRNAs, includ-
ing Xist [20]. A further possibility is that non-coding
portions of the genome may associate with a promoter,
become transcribed, and eventually gain function as an
lncRNA.
Subcellular localisation
If an lncRNA is functional, its location in the cell will be
important in understanding this function. Initial high-
throughput studies have indicated that lncRNAs were
predominantly enriched in the nucleus [7]. However,
an increasing number of cytoplasmic lncRNAs are now
being unearthed [21]. All lncRNAs are transcribed in
the nucleus and so are present there at some level. An
area of active study is to understand which lncRNAs
make it out the of nucleus and why. Enrichment of a
lncRNA in either the nucleus or the cytoplasm does not
preclude it from operating in both compartments. In fact,
it is possible for lncRNAs tomove between the two com-
partments in response to signals (e.g. UCHL1-AS [22]).
Nuclear retention of lncRNAs
Many lncRNAs are enriched in the nucleus and a consid-
erable number have been found to function speciﬁcally
in the nucleus. Within the nucleus, many lncRNAs are
speciﬁcally localised to nuclear sub-compartments
(Figure 4, Table 1), which argues against them being
transcriptional by-products. In fact, lncRNAs have been
found to occupy the nucleolus (PAPAS), nuclear matrix
(XIST), nuclear speckles (MALAT1), and nuclear para-
speckles (NEAT1) (Figure 4). Targeting of lncRNAs to
such speciﬁc locations can be the result of nuclear loca-
lisation signals within the lncRNA itself (e.g. BORG and
MALAT1 [23,24]).
Analysis of nuclear lncRNAs sequences has identiﬁed
speciﬁc motifs enriched in lncRNA correlating with
nuclear fate [25,26]. For instance, a 57 nt motif is
repeated 18 times in Xist, and a 15 nt C-rich element is
found in 21 different lncRNAs, including MALAT1.
Essentially, the presence of several of these motifs in
an lncRNA is more likely to facilitate its nuclear reten-
tion. Several lncRNA sequence elements, which have
evolved from transposable elements (TEs), have also
been characterised as sufﬁcient for nuclear localisation
(e.g. L2B, MIRb, and MIRc TE [27]). Similarly, a less-
stringent analysis revealed the involvement of Alu repeat
motifs in nuclear retention of lncRNAs [28]. The loca-
tion and number of these elements as well as ﬂanking
sequences have been shown to contribute to the strength
of nuclear enrichment.
RNA splicing is important to the export of mRNAs
from the nucleus. Unsurprisingly, inefﬁcient splicing of
lncRNAs has been linked to their nuclear localisation
(e.g. A-ROD lncRNA), and intron retention contributes
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to restricting of lncRNAs to the nucleus [29]. Weak
interactions of lncRNAs with splicing factors
(e.g. MALAT-1 with SRm160 [23]) is also thought to
contribute to nuclear retention. The U1 snRNP complex
keeps lncRNAs in the nucleus in two ways [30,31].
LncRNA exons and introns contain U1 recognition
sites, which U1 snRNP (small nuclear ribonucleopro-
tein) and associated factors have been shown to be
recruited to and antagonise cytoplasmic export [31].
These sequences have been found in nuclear retention
elements. It has also been speculated that U1 spliceo-
some association with U1 recognition sites then contrib-
utes to inefﬁcient splicing and remaining bound to
chromatin. As a result, polyadenylation of these tran-
scripts is impeded, allowing for lncRNA turnover [30].
Those lncRNAs that do not interact with the mRNA
export machinery (e.g. Aly/REF) are more likely to be
enriched in the nucleus [32]. Xist lncRNA is retained
within the nucleus partly as a result of its weak interac-
tions with RNA export proteins such as Nxf1 [33].
Export of some lncRNAs with limited splicing
(e.g. NORAD) is facilitated by splicing-independent
export machinery such as TPR [34].
LncRNAs can be tethered to the nuclear matrix or
nuclear (para)speckles (membrane-less organelles) by
adapter proteins. For example, CIZ1 and hnRNPU,
which can interact with chromatin, facilitate Xist
lncRNA anchoring to the nuclear periphery (Figure 4)
[35,36] and similarly with Bloodlinc [37].
Function of nuclear lncRNAs
As mentioned previously, lncRNAs can interact with
DNA, RNA, and proteins. Nuclear lncRNAs tend to
engage with DNA and protein (Figure 3) to regulate
gene expression in a variety of ways (Figure 5). For
instance, lncRNA PAPAS binds both DNA and protein
to elicit its function. PAPAS interacts with the CHD4/
NuRD (nucleosome remodelling and deacetylation)
complex and can engage in RNA–DNA triplex forma-
tion to ‘scout’ for its DNA recognition element, effec-
tively guiding chromatin remodellers to sites necessary
for gene-expression regulation [38] (Figure 5A).
lncRNA MEG3 interacts with DNA to guide chromatin
remodellers, interacts with itself (lncRNA:lncRNA)
[39], and acts as a co-activator of p53, partially regulat-
ing p53 target genes [40] (Figure 5B, C). Although
lncRNA Jpx competes with DNA for CTCF protein
docking, the action of titrating CTCF away from one
of the two X chromosomes in mice contributes to X
chromosome inactivation (Figure 5D).
Cytoplasmic lncRNAs
Export of lncRNAs to the cytoplasm is usually indica-
tive of a speciﬁc function, given that some level of activ-
ity is required. A recent study in the human chronic
myelogenous leukaemia cell line (K562) revealed that
54% of expressed lncRNAs are detected in the cyto-
plasm [27]. The majority of 50-capped, spliced, andTa
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Figure 4. Localisation of nuclear lncRNAs to speciﬁc nuclear regions and their dynamic nature. lncRNAs generated in the nucleus can be
anchored at speciﬁc locations (e.g. XIST) or dynamically shift their intra- and inter-cellular localisation in response to environmental cues
such as heat shock (e.g. PAPAS) or metabolic stress (e.g. UCHL1-AS). Created using BioRender.
Figure 5.Molecular functions of nuclear lncRNAs. (A) lncRNAs can guide chromatin remodelling complexes to transcription sites, which can
either deposit active or repressive chromatin marks (e.g. Xist). (B) lncRNA:RNA interactions can cause a shift in tertiary structure, activating
transcription factors which regulate gene expression (e.g. MEG3). (C) By bridging protein interactions or scaffolding the assembly of multi-
protein complexes, lncRNAs can facilitate enhancer and promoter element interactions, critical for gene activation (e.g. HOTTIP). (D) IncRNAs
bind speciﬁc proteins with high afﬁnity to titrate proteins away from typical occupancy sites, impacting gene activity and/or 3-D genome
compaction (e.g. Jpx). Created using BioRender.
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polyadenylated lncRNAs ‘get the green light’ to reach
the cytoplasm. Methylation of adenosine (N6-Methyla-
denosine, m6A) in lncRNAs, like mRNAs, stimulates
their export to the cytoplasm. For mRNAs, this is medi-
ated by YTHDC1, which binds to the modiﬁed base and
helps recruit nuclear export factors ([41] and references
therein). Although there is no direct evidence, this is
probably also the case for lncRNAs. Although the pres-
ence of some speciﬁc TEs promote nuclear lncRNA
retention, some classes of TEs (e.g. the endogenous ret-
rovirus class ERVL-MaLR) are enriched in cytoplasmic
lncRNAs [27]. This suggests that there are speciﬁc
sequence determinants of lncRNAs being localised to
the cytoplasm. Of interest, lncRNA localisation to the
cytoplasm can be affected by external cues and, there-
fore, can change. For example, UCHL1-AS shifts from
the nucleus to the cytoplasm upon stress induction with
rapamycin in mouse dopaminergic MN9D cells [22].
As in the nucleus, cytoplasmic lncRNAs can form
ribonucleoprotein complexes by binding mRNAs and
proteins, or by competing with mRNAs for binding to
a speciﬁc protein (Figure 6A). lnc MyoD, which plays
a key role in the regulation of myogenesis, is one such
an example. It interacts strongly with IGF2 mRNA-
binding proteins (IMPs), and negatively regulates
IMP2-mediated translation of proliferation genes such
as N-Ras and c-Myc by antagonising those mRNAs for
IMP binding, thus promoting cell cycle exit and differen-
tiation [42].
Some lncRNAs harbour miRNA-binding sites and by
having multiple sites can act as ‘molecular sponges’,
sequestering miRNAs and therefore protecting mRNAs
from miRNA-mediated degradation. These lncRNAs
are termed competing endogenous RNAs (ceRNAs)
[43]. One such molecular sponge is the lncRNA regula-
tor of reprogramming (linc-RoR), which interacts with
miR-145 (Figure 6B).
As alreadymentioned, many lncRNAs are capped and
polyadenylated [7,17]. If these lncRNAs are present in
the cytoplasm, they can interact with ribosomes
(Figure 6C) and be translated (Figure 6D). In fact, a
number of studies in human, mouse, ﬂy, and yeast have
detected lncRNAs in ribosome-bound complexes by
ribosome proﬁling [44–46]. This RNA-Seq–based
method, which detects translation events, has revealed
that small open reading frames (smORFs, <100 aa) pre-
sent in some lncRNAs are actually translated. Given that
many cytoplasmic lncRNAs possess the same molecular
characteristics as mRNAs, this should not be that sur-
prising. Should these translated lncRNAs be re-
classiﬁed as mRNAs? Because lncRNAs by their very
nature lack long open reading frames, these translation
events generally can produce only small peptides. These
lncRNA–ribosome interactions remain controversial, as
they could represent non-speciﬁc interactions rather than
bonaﬁde translation events.
In addition to lncRNAs being actively engaged by
ribosomes, lncRNAs can also associate with mRNAs
Figure 6.Molecular functions of cytoplasmic lncRNAs. (A) lncRNAs interact with proteins and/or mRNAs to form RNP complexes, which reg-
ulate post-transcriptional gene regulation. (B) lncRNAs act as molecular sponges for miRNAs, thus stabilising and protecting mRNAs from
degradation. (C) lncRNAs associate with the translation machinery and regulate the translation of mRNAs. (D) lncRNAs can be actively
engaged by translating ribosomes. (E) lncRNAs have been found in extracellular vesicles. Created using BioRender.
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during translation [22] (Figure 6D). Several lncRNAs
are associated with large translation complexes (poly-
somes), but they themselves are not translated. These
polysome-associated lncRNAs tend to exhibit wide-
spread expression patterns across different human tis-
sues. They are also more likely to be enriched in the
cytoplasm compared to free cytoplasmic lncRNAs
[27]. This suggests that these polysome-associated
lncRNAs are more likely to be functional than those pre-
sent just in the cytosol.
Cytoplasmic lncRNAs may localise to speciﬁc organ-
elles or cytoplasmic structures. Notably, some cytoplas-
mic lncRNAs are encoded by mitochondrial DNA, and
are therefore found and operate in the mitochondria
[18,47]. lncRNAs participate in the formation of P-
bodies and extracellular vesicles (EVs), the latter of
which are secreted from one cell and received by
another, acting as cellular messengers (Figure 5E). It
has been suggested that lncRNA molecules with rela-
tively low expression levels (e.g. lincRNA-p21,
HOTAIR) are highly enriched in exosomes (Table 1)
[48]. The level of secretion of lncRNAs is critical for cell
homeostasis, as it has been shown that lncRNA exosome
levels reﬂect the cellular response to DNA damage [48].
LincRNA-p21 transcript levels in exosomes isolated
from urine samples of prostate cancer patients appear
to be signiﬁcantly elevated compared to those of patients
with benign prostatic hyperplasia [49]. Therefore,
LincRNA-p21 could serve as a biomarker for the differ-
ential diagnosis between prostate cancer and benign
prostatic hyperplasia.
LncRNA roles in development and differentiation
LncRNAs have been found not only to be spatially
restricted but also temporally, that is, at certain stages
in development. Speciﬁc expression of a lncRNA during
development suggests that it may have an important
function at that time. Several such lncRNAs have been
characterised. Probably the most well-known lncRNA
is XIST (Table 1), a nuclear-retained lncRNA that is 50
capped, polyadenylated, and alternatively spliced
(~19.2 kb in human) [50]. XIST is important during
early development, functioning in X chromosome inacti-
vation (XCI) as part of dosage compensation. Mutations
in mouse Xist result in an inability to undergo XCI and
embryonic lethality [51,52].
To ensure an equal dosage of X-linked genes between
females and males, one of a female’s two X chromo-
somes is inactivated. Post-differentiation, Xist is
expressed speciﬁcally in females. In humans, XIST is
lowly expressed from day 4 shortly after zygote forma-
tion, increasing at days 6 and 7 post-fertilisation with
randomXCI taking place on day 7 [53]. The precise tim-
ing of XCI differs in diverse placental mammals [54], as
does Xist’s precise temporal expression. Studies in
human and mouse stem cells suggest that Xist recruits
protein partners, forming several lncRNA–protein
complexes and covering one X chromosome to inacti-
vate it. Xist recruits SPEN to initiate gene silencing
[55–58], and then, via hnRNPK, PRC1, and PRC2 com-
plexes, to deposit repressive chromatin marks to estab-
lish and maintain gene silencing (Figure 5A, [59]).
hnRNPU and CIZ1 tether Xist to the nuclear periphery
(Figure 4) [35,36,60,61].
The establishment of the three germ layers (lineage
speciﬁcation) from the embryonic epiblast is a critical
point in development. lncRNAs have been found to con-
trol the direction of stem cell differentiation and hence
contribute to cell identity decisions. For instance, yylncT
lncRNA has been detected in the nucleus of day 2 human
embryonic stem cells (hESCs) following mesoderm
speciﬁcation [62]. Disruption of yylncT transcription
or its depletion in differentiating hESCs leads to
decreased levels of the transcription factor Brachyury,
a master regulator of mesoderm speciﬁcation, resulting
in increased apoptosis and downregulation of key meso-
derm driver genes. yylncT lncRNA safeguards both its
own and the Brachyury locus from genome-wide meth-
ylation in response to differentiation signals [62].
Cytoplasmic lncRNAs are also important in pluripo-
tency and differentiation by interacting with key pluripo-
tency factors. Linc-RoR has been shown to crosstalk
with some of these factors, namely OCT4, SOX2, and
NANOG, speciﬁcally in self-renewing hESCs. In fact,
linc-RoR levels are markedly reduced in differentiated
hESCs, implying a key role in pluripotency [63]. Linc-
RoR can act as a ceRNA to sequester miR-145, which
negatively modulates OCT4, SOX2, and NANOG
mRNA levels (Figure 6B). Essentially, linc-RoR can
block exit from pluripotency via an miR-145-mediated
OCT4 downregulation pathway in the cytoplasm. Linc-
RoR also deregulates the pluripotency transcription fac-
tor SOX9 through competition with miR-15b, miR-33a,
miR-129, miR-145, and miR-206, in human oesopha-
geal squamous cell carcinoma cells and patients’ sam-
ples, resulting in Sox9 stabilisation and promotion of
oncogenesis [64]. Upregulation of linc-RoR has been
linked to the increased occurrence of cancers such as tri-
ple negative breast cancer [65], and endometrial [66],
nasopharyngeal [67], and liver cancers [68].
Determination of the anterior–posterior axis is medi-
ated by the coordinated expression of Hox genes. Along
withHox protein-coding genes, Hox lncRNAs have also
been shown to participate in regulating this process.
HOTTIP is a Hox lncRNA that is functionally conserved
across developing mice, chick embryos, and humans. It
modulates precise spatial and temporal expression pat-
terns ofHox genes, ensuring proper embryonic develop-
ment. Chick embryos with reduced HOTTIP expression
exhibit defects in limb development [69]. HOTTIP
lncRNA can recruit histone methyltransferase com-
plexes to deposit gene activation chromatin marks
(i.e. H3K4me3) on the 50 Hox-A locus (Figure 5). These
examples illustrate how important lncRNAs are to devel-
opment, acting as gatekeepers for cell viability or cell
fate speciﬁcation.
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LncRNAs in cancer
It is evident that lncRNAs play decisive regulatory roles
at crucial checkpoints between proliferation and differ-
entiation. When this regulation is disrupted, disease is
the inevitable consequence. Although early work uncov-
ered lncRNAs associated with cancer, there are now
functionally characterised lncRNAs whose contribution
to cancer progression and phenotype has been elucidated
at a more mechanistic level.
NBAT-1 is a well-studied lncRNAwith a deﬁned role
in cancer, the mechanism of action for which has
recently been elucidated. Like many lncRNAs,
NBAT-1 exhibits tissue speciﬁcity and is expressed
mainly in the brain, breast, and ovary. Notably, some
regions of NBAT-1 have substantial sequence conserva-
tion across mammals, suggesting an evolutionarily con-
served function [70]. Cancer patients with high NBAT-1
expression have been associated with good prognosis,
whereas patients with low NBAT-1 expression have
been associated with poor prognosis [70]. NBAT-1 con-
tains a high-risk associated single nucleotide polymor-
phism (SNP) within its intron, which contributes to
regulating its expression levels (A/A genotype higher
NBAT-1 expression, G/G genotype lower NBAT-1
expression). In high-risk patients, DNA methylation
functions to inactivate the NBAT-1 promoter, leading
to downregulation of expression and consequently to
cell proliferation and invasion. The SNP and NBAT-1
promoter may together be involved in higher order regu-
latory interactions.
Suppression of NBAT-1 by knockdown in the SH-
SY5Y human neuroblastoma cell line results in
increased cancer cell viability and invasiveness, whereas
overexpression leads to decreased cell proliferation and
invasion. Furthermore, mouse xenografts developed
from NBAT-1–depleted cells showed a substantial
increase in growth rate. RNA-seq of NBAT-1 knock-
down in SH-SY5Y identiﬁed several genes associated
with cell proliferation and migration that are regulated
byNBAT-1. Among these areVCAN, SOX9, andOSMR,
which contribute to cancer progression [71,72].
NBAT-1 lncRNA interacts with the PRC2 complex
member EZH2 to suppress target genes implicated in
cell proliferation and cell migration via chromatin level
regulation [70]. Taken together, these ﬁndings suggest
that NBAT-1 is a ‘protector’ against neuroblastoma
(Figure 7A).
On the other hand, some lncRNAs that are misregu-
lated in cancer act to promote tumour growth and resis-
tance to chemotherapy. One such example is LINK-A
(LINC01139; long intergenic non-coding RNA for
kinase activation). The LINK-A locus is ampliﬁed in
multiple cancer types, and high expression levels of
LINK-A are correlated with poor prognosis in breast
cancer patients (Figure 7B) [73]. Of interest, LINK-A
is cytoplasmic in adenocarcinoma lung cells and SK.
N.SH cells, but nuclear in HeLa and NHEK cells
[21]. This suggests that it shuttles between the nucleus
and cytoplasm. LINK-A belongs to the category of
lipid-binding lncRNAs, and speciﬁcally binds to phos-
phatidylcholine, AKT, and PIP3, resulting in AKT
hyperactivation that leads to tumorigenesis and resis-
tance to AKT inhibitors [73]. LINK-A interacts with
PIP3 through a 60 nt RNA oligonucleotide motif
(nt 1081–1140), containing a stem-loop structure essen-
tial for this interaction. Furthermore, LINK-A–PIP3
interaction confers resistance to anti-tumour drugs such
as perifosine and MK2206.
Mechanisms of action at the molecular level and asso-
ciation with cancer have been studied for a substantial
number of lncRNAs so far. There seem to be two distinct
patterns of action: they can either inhibit cancer cell pro-
liferation and invasion, or promote tumour growth and
metastasis.
LncRNAs and neurodegeneration
About 40% of human lncRNAs (equivalent to
4000-20 000 lncRNA genes) are speciﬁcally expressed
in the brain [7], where they display an exquisite spatio-
temporal expression proﬁle as well as cellular localisa-
tion variability [74]. lncRNAs are involved in key
regulatory mechanisms during various stages of neuro-
genesis and synaptic plasticity. Therefore, it is not sur-
prising that the misregulation of several lncRNAs
contributes to the development of neurodegenerative
diseases.
Primate-speciﬁc brain cytoplasmic RNA BC200
(or BCYRN1) and its rodent orthologue (BC1) are cyto-
plasmic anti-sense lncRNAs highly expressed in the
brain (Table 1) and have been implicated in Alzheimer’s
disease (AD). They both regulate mRNA translation,
selectively target to somatodendritic domains of human
neurons, and contribute to the maintenance of long-term
synaptic plasticity [75]. Speciﬁcally, they have been
reported to repress translation initiation in dendrites
[76] (Figure 7C). BC200 exhibits a diffuse localisation
in dendritic domains of neuropils and its levels are
reduced during ageing. In AD, BC200 is upregulated in
speciﬁc areas of the neocortex, where it forms character-
istic clusters mislocalised in cell soma rather than in the
synapse [75]. It seems to disrupt mRNA localisation to
the synapse, which is required for proper synapse func-
tion [77]. Levels of BC200 across different parts of the
brain correlate with the severity of the disease in these
brain regions [75], further suggesting an important role.
The recently characterised lncRNA UCHL1-AS has
been associated with Parkinson’s disease and exhibits a
dynamic subcellular localisation (Table 1). UCHL1-AS
is in the anti-sense orientation to UCHL1, which pro-
duces a neuron-restricted protein, essential for develop-
ment. UCHL1-AS is conserved between mouse and
human. It is highly expressed in the murine ventral mid-
brain and inmouseMN9D dopaminergic cells [22]. Nor-
mally UCHL1-AS accumulates in the nucleus of
dopaminergic neurons. Upon cellular stress induced by
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rapamycin (inhibitor of cap-dependent translation),
UCHL1-AS translocates to the cytoplasm where it pro-
motes translation of UCHL1 mRNA by increasing its
association with heavy polysomes [22]. UCHL1-AS is
downregulated in a mouse neurochemical model of
Parkinson’s disease [78].
Huntington’s disease (HD) is caused by a CAG trinu-
cleotide repeat expansion in exon 1 of the huntingtin
gene, HTT [79]. Several well-studied lncRNAs, such as
NEAT1 and MEG3, have been associated with HD
[80]. A recently discovered anti-sense lncRNA, HTT-
AS, regulates the expression of HTT [79]. HTT-AS is
50 capped, polyadenylated, and can be alternatively
spliced [79]. HTT-AS levels are reduced by 50% in
HD brains compared to controls, and it negatively regu-
latesHTT expression. Knockdown of HTT-AS leads to a
20% increase of HTT, whereas overexpression of HTT-
AS decreases endogenous HTT expression by 25%
[79] (Figure 7D).
These three lncRNAs highlight how lncRNA misre-
gulation is implicated in neurodegeneration. Each of
them acts at a different level of gene expression regula-
tion, a key feature of lncRNAs in general.
LncRNAs as biomarkers and therapeutic targets
Despite the small number of functionally characterised
lncRNAs, their potential as biomarkers or therapeutic
agents is quickly being realised. Following the huge
progress in elucidating the mechanisms of action and
the association of lncRNAs with disease, the scientiﬁc
community is now keen to investigate the possibility
of using lncRNAs as prognostic or diagnostic bio-
markers. This approach is based on the initial observa-
tions that the levels of certain lncRNAs in blood
samples correlates with the occurrence of a disease. In
a preclinical setting, lncRNAs have been suggested as
potential diagnostic or prognostic biomarkers affecting
a variety of tissues including the heart (MALAT1),
reproductive system (H19), muscle (linc-MD1), and
Figure 7. lncRNAs can promote or protect from cancer and neurodegeneration. (A) NBAT1-lncRNA promotes neuronal differentiation and
prevents neuroblastoma. (B) LINK-A interacts with PIP3, PC, and AKT, resulting in AKT hyperactivity and drug resistance in breast cancer.
(C) BC200 disrupts mRNA delivery and translation at the synapse and leads to neurodegeneration. (D) HTT-AS controls HTT expression levels.
Downregulation of HTT-AS has been linked to the occurrence of Huntington’s disease. Created using BioRender.
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several cancer types (MALAT1, H19, MEG3,
HOTAIR) (reviewed in [81,82]).
LncRNAs are ideal biomarker candidates because of
their high tissue speciﬁcity. This may enable the detec-
tion of metastasis, or perhaps help alleviate the complex-
ity imposed by cancer heterogeneity [81]. As mentioned,
lncRNAs can be encapsulated in EVs and so have the
potential to end up in the blood stream, also making
them ideal biomarkers [83]. The temporal restriction of
some lncRNAs could add another layer to biomarker
speciﬁcity, or even allow for the tracking of disease pro-
gression. Several lncRNAs have already been explored
for these reasons, but none have reached clinical
trials yet.
GAS5 lncRNA is being currently studied at a pre-
clinical level as a potential biomarker for type 2 diabetes
(T2D) and coronary artery disease (CAD). GAS5 is
readily detected in human serum and its levels are corre-
lated to the prevalence/onset/appearance of T2D. Specif-
ically, GAS5 is signiﬁcantly downregulated in diabetic
patients compared to healthy controls [84], and signiﬁ-
cantly lower in patients with CAD compared to patients
with diabetes mellitus [85].
NBAT1 also has the potential to serve as a prognostic/
diagnostic marker for different types of cancer.
Although it is not being tested in clinical trials yet, there
is substantial pre-clinical evidence from patient samples.
It is differentially expressed in transcriptomic proﬁling
of 15 neuroblastomas of different types [70]. NBAT-1
can be utilised for differential diagnosis, because
patients with high NBAT-1 are associated with good
prognosis and vice versa [70]. NBAT-1 levels are con-
siderably lower in bladder cancer samples compared to
healthy controls [86].
SNGH1 could represent a novel lncRNA biomarker of
tumorigenesis for a number of tissue biotypes including
brain, breast, lung, liver, and ovary [87]. SNGH1
lncRNA can be detected at a higher level in tissues from
patients with colorectal carcinoma compared to healthy
individuals. It is important to note that high levels corre-
late with tumour malignancy, reﬂected in poorer patient
survival compared to those with lower SNGH1 levels. In
cell lines, enhanced apoptosis and diminished cell prolif-
eration were observed when SNGH1 was decreased,
suggesting it might represent a therapeutic target as well
as acting as a potential biomarker.
RNA therapeutics is a newly emerging but rapidly
expanding ﬁeld. Most approaches so far have included
targeting an offending RNA molecule with small mole-
cule drugs or using anti-sense oligos to speciﬁcally inter-
fere with RNA function. Using RNAmolecules as drugs
is also being explored by industry. Targeting the biogen-
esis of lncRNAs is currently being pursued in cancer cell
lines [88,89]. This approach has been employed previ-
ously with miRNAs (reviewed in [90]).
LncRNAs themselves could act as therapeutic mole-
cules. One approach has been described whereby
lncRNAs harbouring tuneable sequence elements (known
as SINE-UPs) can be tailored to target mRNAs and spe-
ciﬁcally increase their translation. This highly
customisable approach could be adapted for any disease
where physiological protein levels are disrupted in a cell,
such as Friedreich’s ataxia [91]. These elements on spe-
ciﬁc lncRNAs can also be multiplexed to target a series
of transcripts in parallel, achieving multiple target
regulation.
Therapeutic strategies to modulate lncRNA activity
have nowmade it to clinical trials. Abivax has developed
a small molecule that has entered phase 2 clinical trials
for ulcerative colitis and moderate to severe stage rheu-
matoid arthritis patients [92–94]. It increases splicing
of lncRNA 0599-205, upregulating production of miR-
124 due to this lncRNA harbouring one of three miR-
124 loci in the genome [95]. miR-124 has been shown
previously to reduce pro-inﬂammatory cytokines and
also regulate innate and adaptive immunity. Thus, by
increasing the levels of spliced lncRNA 0599-205,
miR-124 production is increased and inﬂammation in
arthritis is reduced [95].
It is too early to speculate on whether lncRNA thera-
peutics will be widely applicable. Nonetheless, there is
growing interest in developing and adapting lncRNAs
from a preclinical to a clinical setting. The more we
understand the function of lncRNAs and how they con-
tribute to disease, the more they can be exploited as ther-
apeutic targets.
Concluding remarks
There are more than 16 000 lncRNA genes in the human
genome, but we currently understand the function of
only ~50. Our improved appreciation of lncRNAs is
changing the way we think about our genomes and
genetic diseases. The simplistic view that lncRNAs
remain in the nucleus to regulate transcription has been
expanded in the last 5 years to appreciate the various
ways both cytoplasmic and nuclear lncRNAs can act.
In fact, their movement between cell compartments
may be dynamic, and their roles can vary depending on
their cellular location.
The low abundance and highly speciﬁc expression
patterns of lncRNAs have made studying them difﬁcult.
Function has also been incorrectly assigned to lncRNAs
based on CRISPR experiments, and now siRNAs are the
preferred method to downregulate lncRNAswithout cre-
ating genomic alterations, which may be lncRNA inde-
pendent. Not all lncRNAs possess a function and
determining which do and which do not is a substantial
body of research. Conservation analysis will contribute
to this understanding and identify model systems in
which research can be performed. Those lncRNAs
whose function has been determined have been found
to contribute to development, neural function, and can-
cer (Figure 7).
We have also made signiﬁcant progress from simple
disease association to mechanistic insights to reveal how
lncRNAs contribute to disease phenotypes. This in turn
allows lncRNAs to be used as therapeutic targets as well
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as biomarkers. Given the number of human lncRNAs,
they provide a vast screening space whose potential has
yet to be fully realised. Further work to precisely map
mutations to genetic diseases will no doubt uncover many
more lncRNAs whose disruption gives rise to disease.
Studies such as the 100 000 Genomes Project will be
key to uncovering precise links with pathology.
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Glossary of terms
Homology: similarity of a nucleotide or amino acid
sequence between species. In cis: function of a transcript
at or very close to the site of its transcription. In trans:
function of a transcript away from the site of its tran-
scription.Orthologues: homologous genes found in dif-
ferent species following a speciation event, for which
gene sequences and main function are conserved. Ribo-
nucleoprotein complexes (RNPs): complexes formed
by RNAs interacting with RNA-binding proteins. Ribo-
some proﬁling/Ribo-Seq: high-throughput sequencing
of small RNA fragments-protected by ribosomes. Syn-
teny: physical co-localisation of genetic loci on the same
chromosome within an individual or species. ENCODE
project: ENCyclopedia Of DNA Elements project is a
public research project aiming to identify functional ele-
ments in the human genome. m7G cap: methyl guano-
sine nucleotide added at 50 end of mRNA to protect it
from degradation and facilitate ribosome binding during
translation. CNS: central nervous system.
Abbreviations
AD, Alzheimer’s disease; CAD, coronary artery disease;
ceRNA, competing endogenous RNA; EV, extracellular
vesicle; HD, Huntington’s disease; hESC, human
embryonic stem cell; IMP, IGF2 mRNA-binding pro-
tein; lincRNA, long intergenic non-coding RNA;
lncRNA, long non-coding RNA; m6A, N6-
Methyladenosine; nt, nucleotide; RBP, RNA-binding
protein; smORF, small open reading frame; snRNP,
small nuclear ribonucleoprotein; SNP, single nucleotide
polymorphism; T2D, type 2 diabetes; TE, transposable
element; UTR, untranslated region; XCI, X chromo-
some inactivation.
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